Fevertree (LON:FEVR) is the name behind the world’s most popular premium tonic. The stock has lost 44% of its value in just under a year, as analysts point to the likelihood of a domestic growth plateau. I agree with this re-evaluation of the company’s domestic prospects; however, investors should see this lull in share price appreciation as an opportunity to buy before business blows up in America.
There are three main parts of my thesis. Firstly, Fevertree is reaching the end of fast growth in its domestic market. This realization amongst investors has hurt the